TP73 and colorectal cancer: Our results, achieved using 145 plasma samples from colorectal cancer (CRC) patients, patients carrying premalignant colorectal lesions, and controls, demonstrated that ΔNp73 showed a specific seroreactivity different from that of p73 with a higher diagnostic ability to discriminate between colorectal cancer patients, and controls, and especially premalignant individuals and controls which may have an important impact on cancer prevention to predict premalignant tumours.